Cell Death and Disease (May 2022)

CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer

  • Shaochuan Liu,
  • Yuan Meng,
  • Liang Liu,
  • Yingge Lv,
  • Wenwen Yu,
  • Ting Liu,
  • Limei Wang,
  • Di Mu,
  • Qiuru Zhou,
  • Min Liu,
  • Yulin Ren,
  • Dong Zhang,
  • Baihui Li,
  • Qian Sun,
  • Xiubao Ren

DOI
https://doi.org/10.1038/s41419-022-04882-x
Journal volume & issue
Vol. 13, no. 5
pp. 1 – 12

Abstract

Read online

Herein, Liu and colleagues show that CD4+ T cells in cytokine-induced killer (CIK) cells are required to enhance the clinical efficacy of CIK therapy. In addition, CD4+ T cells help via IL-17A production is critical to restoring the function of CD8+/CD3+CD56+ T cells and reversing the exhaustion of PD-1+TIM-3+ T cells in CIK therapy.